Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

27.21 -0.24 (-0.87%)
Streaming Delayed Price Updated: 10:08 AM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
19 20 Next >
News headline image
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
3 Penny Stocks That Could Skyrocket in the Next 12 Months ↗
Find the top penny stocks to buy, and you can make a fortune. Pick the wrong one and there are also plenty of horrors. 
Via InvestorPlace
News headline image
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Over $5M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
ACADIA Pharmaceuticals's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
What 22 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
ACADIA Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Analyst Ratings for ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Records 52-Week High Tuesday Morning
Via Investor Brand Network
News headline image
Top 5 Health Care Stocks That Should Keep You Up At Night ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Analyst Ratings for ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment ↗
 
Via Benzinga
News headline image
1 Top Biotech Stock to Buy in March ↗
This biotech could land a major regulatory approval this month. 
Via The Motley Fool
News headline image
Looking Into ACADIA Pharmaceuticals's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher ↗
ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. What Else? 
Via Benzinga
News headline image
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
News headline image
Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug ↗
The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older. 
Via Benzinga
News headline image
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on... 
Via Benzinga
News headline image
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket ↗
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of... 
Via Benzinga
News headline image
3 Nasdaq Stocks on Watch This Week ↗
These three Nasdaq stocks are poised to make big moves in the coming week. 
Via The Motley Fool
News headline image
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACADIA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
From Kahn Swick & Foti, LLC
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.